PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) as we speak introduced that Veeva eConsent, a MyVeeva for Patients utility constructed on Veeva Medical Community, had its first affected person full an digital consent for an early section medical trial by Crofoot Analysis Heart. Veeva eConsent is the primary validated utility for websites and sufferers that transforms the consent course of from handbook and paper-based to an end-to-end digital expertise. Sufferers can evaluate paperwork and protocols and supply consent by way of cell phone, streamlining the expertise for each sufferers and websites.
“As one of many first websites utilizing Veeva eConsent, we’re excited to collaborate with Veeva to assist the business shift from paper to digital consent for the advantage of sufferers and medical analysis,” mentioned Charles Sydnor, CCRA, ACRP-CP, venture supervisor at Crofoot Analysis Heart. “Veeva eConsent makes the method straightforward for our sufferers and permits us to interrupt down the limitations of paper and site, increasing the attain of our research.”
COVID-19 accelerated the business’s transfer to digital options that allow decentralized trials and hold research on observe, velocity research start-up, and enhance trial execution. Veeva eConsent permits this transformation by means of digital consent doc creation, approval, and change. Websites can use the appliance for trials throughout sponsors and automate the circulate of consent paperwork to the investigator website file (ISF) for higher collaboration and higher velocity.
With Veeva eConsent, sponsors get real-time visibility into affected person consent standing, date, and model and displays and website personnel acquire distant entry to trial data. Decreasing the time spent on administrative duties will increase website and affected person engagement all through a research.
“In simply six months, we went from idea to the primary affected person utilizing Veeva eConsent,” mentioned Tim Davis, vice chairman, MyVeeva for Sufferers at Veeva Methods. “This marks a serious step ahead for the way forward for paperless, patient-centric trials and we stay centered on persevering with to ship improvements that can assist the business understand this vital imaginative and prescient.”
Attend the upcoming webinar on April 29 to listen to Crofoot talk about how Veeva eConsent helps websites run extra environment friendly medical trials and to study extra about Veeva Medical Community, the business’s solely answer that connects sponsors, websites, and sufferers to speed up medical analysis.
About Veeva Methods
Veeva is the worldwide chief in cloud software program for the life sciences business. Dedicated to innovation, product excellence, and buyer success, Veeva serves greater than 975 clients, starting from the world’s largest pharmaceutical corporations to rising biotechs. As a Public Profit Company, Veeva is dedicated to balancing the pursuits of all stakeholders, together with clients, workers, shareholders, and the industries it serves. For extra data, go to veeva.com.
This launch comprises forward-looking statements, together with the market demand for and acceptance of Veeva’s services, the outcomes from use of Veeva’s services, and normal enterprise circumstances (together with the on-going influence of COVID-19), notably inside the life sciences business. Any forward-looking statements contained on this press launch are based mostly upon Veeva’s historic efficiency and its present plans, estimates, and expectations, and aren’t a illustration that such plans, estimates, or expectations can be achieved. These forward-looking statements characterize Veeva’s expectations as of the date of this press announcement. Subsequent occasions could trigger these expectations to vary, and Veeva disclaims any obligation to replace the forward-looking statements sooner or later. These forward-looking statements are topic to identified and unknown dangers and uncertainties which will trigger precise outcomes to vary materially. Further dangers and uncertainties that might have an effect on Veeva’s monetary outcomes are included below the captions, “Threat Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations,” within the firm’s submitting on Kind 10-Q for the interval ended October 31, 2020. That is obtainable on the corporate’s web site at veeva.com below the Buyers part and on the SEC’s web site at sec.gov. Additional data on potential dangers that might have an effect on precise outcomes can be included in different filings Veeva makes with the SEC sometimes.